ArticleClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2025
Transcriptome analysis of key genes and pathways associated with cisplatin resistance in oral squamous cell carcinoma Cal27 cells.
Article in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Cisplatin resistance in oral squamous cell carcinoma: mechanisms, reversal strategies, and emerging technologies.Frontiers in physiology · 2026Review
Corrections and comments
- Erratum issued
Authors and funding
11 authors.
Funding
Abstract
backgroundOral squamous cell carcinoma (OSCC) has a poor postoperative recovery and is prone to drug resistance during long-term chemotherapy, but the molecular mechanism of its resistance has not been fully elucidated.
methodsIn the present study, a cisplatin-resistant cell line Cal27R was established and the key genes and pathways associated with drug resistance were explored using bioinformatics analysis and molecular biology experimental techniques.
resultsTranscriptome analysis reveals a total of 1927 differentially expressed genes (DEGs). GO and further KEGG analysis revealed the DEGs were primarily concentrated in the tumor necrosis factor (TNF) and the mitogen-activated protein kinase (MAPK) signaling pathway. PPI network analysis identified six genes exhibiting significant interactions. Among these, interrogation of the TCGA database revealed elevated expression levels of TNF, TGFB1, and IL1B in tumors from drug-resistant patients, whereas EGF and FOS expression was significantly downregulated. The level of immune infiltration was positive correlated with the expression of TNF, TGFB1, IL6 and EGF, conversely, negative correlated with that of IL1B. Furthermore, low expression of TNF and FOS, as well as high expression of TGFB1, IL6 and EGF, was associated with poor overall prognosis. Based on the comprehensive analysis above, TNF, TGFB1, and EGF were ultimately selected as target genes to positively regulate the cisplatin resistance of Cal27R cells. Furthermore, we validated the expression of target genes in human tongue carcinoma tissues and paired adjacent normal tissues. Knockout of these genes significantly reduced drug resistance, consistent with our initial hypothesis. Whole-exome sequencing (WES) analysis confirmed the absence of underlying mutations, thereby corroborating the bioinformatics predictions.
conclusionTNF, TGFB1 and EGF were regarded as the key genes associated with cisplatin resistance and poor prognosis in OSCC. Meanwhile, their related TNF and MAPK pathways were considered as the pivotal signaling pathways. Our results provide a theoretical and experimental basis for potential diagnostic and therapeutic targets to address drug resistance in clinical settings.
Indexed as
Identifiers
40227535What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.